Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program by Alexandre de Moura, Perrine Vuagnat, Benjamin Renouf, Jean-Yves Pierga, Delphine Loirat, Pauline Vaflard, Charline Lafayolle de la Bruyère, Natacha Chaumard-Billotey, Nawale Hajjaji, Sylvain Ladoire, Sandrine Dabakuyo, Anne Patsouris, Jean Sébastien Frenel, Vincent Nicolai, Marie Alexandre, Nadine Dohollou, Julien Grenier, Heloïse Bourien, François-Clément Bidard

Get full text

Trastuzumab deruxtecan in previously treated HER2‐positive metastatic or unresectable breast cancer: Real‐life data from the temporary use authorization program in France by Thierry Petit, Nawale Hajjaji, Eric‐Charles Antoine, Marc‐Antoine Benderra, Michel Gozy, Cyril Foa, Jean‐Loup Mouysset, Julien Grenier, Mireille Mousseau, Audrey Mailliez, Mahasti Saghatchian, Emma Lachaier, Isabelle Desmoulins, Audrey Hennequin, Patricia Maes, Delphine Loirat, Francesco Ricci, Véronique Diéras, Dominique Berton, Florence Lai Tiong, Luis Teixeira, Nadine Dohollou, Christelle Lévy, Thomas Bachelot, Jean‐Yves Pierga

Get full text

The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research by Aurélie Moniot, Christophe Schneider, Laure Chardin, Elisa Yaniz-Galende, Catherine Genestie, Marion Etiennot, Aubéri Henry, Coralie Drelon, Audrey Le Formal, Benoit Langlois, Laurence Venat, Christophe Louvet, Laure Favier, Alain Lortholary, Dominique Berton-Rigaud, Nadine Dohollou, Christophe Desauw, Michel Fabbro, Emmanuelle Malaurie, Coraline Dubot, Jean Emmanuel Kurtz, Nathalie Bonichon Lamichhane, Éric Pujade-Lauraine, Albin Jeanne, Alexandra Leary, Stéphane Dedieu

Get full text